Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.

Trial Profile

Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Erlotinib (Primary) ; Gefitinib (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 Status changed from not yet recruiting to recruiting.
    • 24 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top